Ads
related to: macular degeneration treatment- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Appointment Tips
Get Tips And Useful Information
To Talk to your Retina Specialist
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Wet AMD FAQs
Search results
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results
Investing.com· 1 day agoThe therapy showed an average gain in visual acuity, contrasting with the typical loss experienced...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
GuruFocus.com via Yahoo Finance· 21 hours agoIts flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by reducing the frequency ...
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Est
Guru Focus· 23 hours agoThe company, known for its innovative ophthalmic products, reported a significant increase in revenue, surpassing analyst expectations for the quarter. EyePoint Pharmaceuticals Inc is a pioneer ...
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 5 days agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 2 days agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Proj
Guru Focus· 21 hours agoOn May 9, 2024, Lineage Cell Therapeutics Inc (LCTX, Financial) disclosed its financial results for the first quarter of 2024 through an 8-K filing. The clinical-stage biotechnology company, ...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 5 days agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks via Yahoo Finance· 4 days agoApellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 5 days agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...
Bright Sight Eye Care to offer optical services, products in Georgetown
Community Impact· 2 days agoThe new clinic will provide glasses, contacts and eye disease treatment.
Ads
related to: macular degeneration treatment